CELG Celgene Corporation

+1.43  (+2%)
Previous Close 93.31
Open 93.92
Price To Book 6.68
Market Cap 67,146,146,972
Shares 708,741,260
Volume 2,675,096
Short Ratio
Av. Daily Volume 4,244,817

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASH 2018 noted at lowest dose ORR 79%; CR 43%.
Multiple myeloma
Phase 1b initiated.
JCAR017 in combination with durvalumab - PLATFORM
Non-hodgkin Lymphoma
Phase 2b trial initiated 3Q 2017.
Systemic lupus erythematosus (SLE)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data 2H 2019.
sNDA filing due 2Q 2019. However, possibly will be delayed due to pending merger with BMY.
Scalp Psoriasis
Phase 3 data released December 21, 2017 - co-primary endpoints not met.
Newly Diagnosed Follicular Lymphoma
Phase 3 data released at ASH 2016.
Maintenance in Patients with Diffuse large B-cell lymphoma (DLBCL) responding to R-CHOP to induction therapy
Phase 3 data released at ASH December 2016.
Induction and Maintenance in ASCT Eligible
Phase 3 enrollment complete - noted April 27, 2017.
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data released at ASH 2016.
Maintenance in Second-line Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2020.
Relapsed or Refractory Indolent Lymphoma
Phase 3 data released February 6, 2018 - primary endpoint (PFS) met. Presentation at ASCO June 1, 2018 noted PFS of 11.2 months vs. 7.1 months.
Multiple Myeloma - refractory
FDA Approval announced May 28, 2019.
Relapsed or Refractory Follicular Lymphoma
Phase 3 data due mid-2020.
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3 - primary endpoint met.
Psoriatic Arthritis
sNDA filing due 2017
Once daily formulation
FDA Approval announced July 19, 2019.
Behçet’s Disease
PDUFA date April 4, 2020.
Myelodysplastic syndromes (MDS) cancer
Phase 3 trial will not be initiated - noted October 19, 2017.
GED-0301 (CD-003)
Crohn’s disease
Phase 3 trial to discontinue due to lack of efficacy - noted October 19, 2017.
GED-0301 (CD-002)
Crohn’s disease
Phase 3 data estimated 2H 2019.
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 data due 2019.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 data estimated 2H 2019.
CC-486 (Oral Azacitidine)
Low risk/INT-1 transfusion-dependent MDS
Phase 3 data released June 2017 - met the endpoint of a pre-planned interim futility analysis.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
PDUFA date March 25, 2020.
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 3 trial to be initiated 2018.
Ulcerative Colitis
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 3 trial planned for 2018.
Glioblastoma (GBM) cancer
Phase 1/2 MM trials placed on clinical hold - September 7, 2017. AML/MDS trials to continue.
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Approved February 22, 2017.
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 2 updated data at ASH 2016.
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Pivotal data due 2019.
Lico-cel (CD-19 JCAR017) - TRANSCEND
r/r B cell non-Hodgkin lymphoma - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 1/2 ongoing
Adults with advanced B cell malignancies
Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Pivotal program to be initiated 2018.
Non-Hodgkin Lymphoma
Phase 3 trial initiated 4Q 2017.
Crohn's disease
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data released April 25, 2019 did not meet primary endpoint.
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 1 updated data at ASCO June 4, 2019 noted best overall response rate was 82% (18/22), with 46% (10/22) of patients achieving complete remission.
Liso-cel (JCAR017) - TRANSCEND CLL-004
Chronic Lymphocytic Leukemia (CLL)
Phase 1 data due by the end of 2019.
Multiple Myeloma
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 2 trial is initiating.
Liso-cel (JCAR017)
Chronic lymphocytic leukemia (CLL)
Phase 2 trial initiated 4Q 2018.
Relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL)
FDA Approval announced August 16, 2019.
Phase 3 trial is initiating.
Plaque psoriasis
Phase 1/2 data presented at ASCO June 2, 2019. Overall response rate 32% (19/59).
Iberdomide (CC-220) and dexamethasone
Relapsed and/or refractory multiple myeloma (RRMM)
sNDA to be filed by end of 2019.
POMALYST (pomalidomide)
Kaposi’s sarcoma
PDUFA date December 4, 2019 under priority review.

Latest News

  1. Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
  2. U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
  3. UPDATE 2-FDA approves Celgene's bone marrow cancer treatment
  4. Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
  5. Seth Klarman's Baupost Boosts Liberty, Reduces eBay
  6. Agios Rides High on Tibsovo Sales Amid Acute Competition
  7. Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
  8. 5 Top Cancer-Fighting Stocks to Buy Now
  9. Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter
  10. Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
  11. Stocks - Tilray, Canada Goose, Luckin Coffee Fall Premarket
  12. Top Stock Reports: Micron, Sinopec, Celgene & More
  13. Mergers & Acquisitions Take Center Stage in Biotech Industry
  14. JPMorgan Chase set to scoop record fee for Allergan sale
  15. Bristol-Myers Squibb Stock Has Upside — But Mind the Risks
  16. Risk-Takers Have a Reasonable Shot with BMY Stock
  17. BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?
  18. bluebird bio Prepares for Launch
  19. Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
  20. Editas Medicine Remains on Track